Deals and Financing

Roche Licenses Rona ALK7 RNAi Program

Roche obtained an exclusive worldwide license to Rona Therapeutics’ investigational ALK7-targeting RNA interference program for obesity and metabolic disease. Rona is eligible for up to $100 million in combined upfront and near-term milestone payments,…

Pfizer Partners with Enodia on Sec61 Programs

Enodia Therapeutics and Pfizer entered a multi-target research collaboration and license agreement to discover Sec61 inhibitors. Enodia will screen, optimize, and develop candidates during the collaboration term; Pfizer will assume clinical, manufacturing, regulatory, and…